Clinical Trials Browser

NCT02859415 2022-04-05

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

GastrointestinalGenitourinaryOther solid neoplasmSarcomaThoracic

Esophageal Neoplasms, Kidney Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Germ Cell and Embryonal, Sarcoma, Thymus Neoplasms, Colorectal Neoplasms

NCT01624090 2019-12-30

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Phase 2 Terminated

16 enrolled 13 charts

BreastGastrointestinalOther solid neoplasmThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Mesothelioma

NCT01610570 2018-03-02

Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma

Phase 1/2 Terminated

8 enrolled 20 charts

Sarcoma

Bone Neoplasms, Sarcoma, Sarcoma, Ewing